Business Description
Fluicell AB
ISIN : SE0023595459
Total Employee Number:
11Compare
Compare
Traded in other countries / regions
FLUI.Sweden5J90.Germany IPO Date
2018-04-18Description
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.68 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.22 | |||||
Beneish M-Score | -0.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -26 | |||||
3-Year EBITDA Growth Rate | 56.5 | |||||
3-Year EPS without NRI Growth Rate | 56.1 | |||||
3-Year FCF Growth Rate | 48.8 | |||||
3-Year Book Growth Rate | -53.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.69 | |||||
9-Day RSI | 40.8 | |||||
14-Day RSI | 44.31 | |||||
3-1 Month Momentum % | 386.49 | |||||
6-1 Month Momentum % | 440 | |||||
12-1 Month Momentum % | 506.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.33 | |||||
Quick Ratio | 0.88 | |||||
Cash Ratio | 0.2 | |||||
Days Sales Outstanding | 41.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 152.45 | |||||
Operating Margin % | -20.73 | |||||
Net Margin % | -19.79 | |||||
EBITDA Margin % | -15.39 | |||||
FCF Margin % | -71.06 | |||||
OCF Margin % | -8.03 | |||||
ROE % | -17.75 | |||||
ROA % | -12.2 | |||||
ROIC % | -17.52 | |||||
3-Year ROIIC % | 154.74 | |||||
ROC (Joel Greenblatt) % | -290.82 | |||||
ROCE % | -16.48 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.49 | |||||
PB Ratio | 2.92 | |||||
Price-to-Tangible-Book | 16.24 | |||||
EV-to-EBIT | -9.09 | |||||
EV-to-EBITDA | -10.85 | |||||
EV-to-Revenue | 1.66 | |||||
EV-to-FCF | -1.99 | |||||
Price-to-GF-Value | 0.87 | |||||
| Price-to-Net-Current-Asset-Value | 18.99 | |||||
Earnings Yield (Greenblatt) % | -11.01 | |||||
FCF Yield % | -20.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fluicell AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 11.865 | ||
| EPS (TTM) (kr) | -1.71 | ||
| Beta | 1.8456 | ||
| 3-Year Sharpe Ratio | 0.61 | ||
| 3-Year Sortino Ratio | 1.89 | ||
| Volatility % | 308.82 | ||
| 14-Day RSI | 44.31 | ||
| 14-Day ATR (kr) | 4.631449 | ||
| 20-Day SMA (kr) | 35.805 | ||
| 12-1 Month Momentum % | 506.74 | ||
| 52-Week Range (kr) | 7.45 - 67.2 | ||
| Shares Outstanding (Mil) | 1.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fluicell AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fluicell AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 43 days | ||
| General meeting for 2026 | 2026-06-03 13:30 | 47.50 (-9.70%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 22.50 (+33.93%) | ||
| Annual report for 2025 | 2026-04-08 | 14.10 (+22.08%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 | 9.50 (-1.04%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 13.30 (-0.75%) | ||
| Second quarter earnings results for 2025 | 2025-08-15 | 10.90 (+0.93%) | ||
| General meeting for 2025 | 2025-05-14 13:30 | 10.40 (-7.14%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 11.70 (+4.46%) |
Show
Entries
Fluicell AB Frequently Asked Questions
What is Fluicell AB(OSTO:FLUI)'s stock price today?
The current price of OSTO:FLUI is kr30.20. The 52 week high of OSTO:FLUI is kr67.20 and 52 week low is kr7.45.
When is next earnings date of Fluicell AB(OSTO:FLUI)?
The next earnings date of Fluicell AB(OSTO:FLUI) is 2026-08-14.
Does Fluicell AB(OSTO:FLUI) pay dividends? If so, how much?
Fluicell AB(OSTO:FLUI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Fluicell AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers